[email protected]23 Nov, 2021News
Satish Mehta, MD & CEO, Emcure Pharma is currently having a moment under the sun. Emcure?s subsidiary, Gennova, is developing India?s first indigenously developed mRNA COVID-19 vaccine that is currently undergoing phase II and phase III trials. Mehta is confident about meeting the said target of 60 million doses by the end of 2021, despite the logistics challenges. The company is working towards backward integration of its operations to help de-risk the supply chain.
ช่อดอกไม้ไทย
Dverto.ai
Jemima Events Venue
Swipe Political Quiz
Sv388 ⭐️ Khám Phá Nền Tảng Giải Trí
Swosti Grand Bhubaneswar
Iuw88com
Rifiworifiwo
Cadworks India
98 Win